公开(公告)号：US20220265547A1

公开(公告)日：2022-08-25

申请号：US17501287

申请日：2021-10-14

Applicant: Lundbeck Pharmaceuticals LLC

Inventor： James CLOYD ,  Angela BIRNBAUM ,  Ilo LEPPIK ,  Stephen D. COLLINS

IPC: A61K9/00 ,  A61K31/724 ,  C08B37/16 ,  A61K31/55 ,  A61K47/40

Abstract: The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.

公开(公告)号：US20210196623A1

公开(公告)日：2021-07-01

申请号：US16939390

申请日：2020-07-27

Applicant: Lundbeck Pharmaceuticals LLC

Inventor： James CLOYD ,  Angela BIRNBAUM ,  Ilo LEPPIK ,  Stephen D. COLLINS

IPC: A61K9/00 ,  A61K31/724 ,  C08B37/16 ,  A61K31/55 ,  A61K47/40

Abstract: The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.

公开(公告)号：US20240165125A1

公开(公告)日：2024-05-23

申请号：US18336419

申请日：2023-06-16

Applicant: Lundbeck Pharmaceuticals LLC

Inventor： James CLOYD ,  Angela BIRNBAUM ,  Ilo LEPPIK ,  Stephen D. COLLINS

IPC: A61K31/55 ,  A61K9/00 ,  A61K31/724 ,  A61K47/40 ,  A61K47/69 ,  B82Y5/00 ,  C08B37/16

CPC classification number: A61K31/55 ,  A61K9/0019 ,  A61K31/724 ,  A61K47/40 ,  A61K47/6951 ,  B82Y5/00 ,  C08B37/0012 ,  C08B37/0015

Abstract: The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.

公开(公告)号：US20180153797A1

公开(公告)日：2018-06-07

申请号：US15657470

申请日：2017-07-24

Applicant: Lundbeck Pharmaceuticals LLC

Inventor： James CLOYD ,  Angela BIRNBAUM ,  Ilo LEPPIK ,  Stephen D. COLLINS

IPC: A61K9/00 ,  A61K31/55 ,  A61K47/40 ,  A61K31/724 ,  C08B37/16

CPC classification number: A61K9/0019 ,  A61K31/55 ,  A61K31/724 ,  A61K47/40 ,  C08B37/0012 ,  C08B37/0015

Abstract: The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.